Conventional allergy tests tell you what you may be allergic to. Molecular testing tells you why — and whether the reaction is clinically significant or just cross-reactive noise.
June 2026 · 8 min read · Lambert Medical Clinical Team
Most people who visit an allergy clinic leave with a list: positive to grass, positive to cat, positive to peanut. What they often don't leave with is an understanding of what those positives actually mean — whether each reaction carries genuine clinical risk, or whether several positives are driven by the same underlying sensitisation and only one of them matters.
Molecular allergy testing was developed specifically to answer that question. This guide explains the science behind it in plain language, without assuming prior immunology knowledge.
Conventional allergy testing — skin prick tests and standard specific IgE blood tests — uses whole allergen extracts. When you're tested for grass pollen, the reagent contains hundreds of different proteins all present in grass pollen. A positive test means your immune system has produced IgE antibodies to at least one of those proteins. But it doesn't tell you which one.
This matters because different proteins within the same allergen source carry very different clinical implications:
Peanut contains around 17 identified protein components. The ones that matter most clinically are:
| Component | Protein family | Clinical significance | Risk level |
|---|---|---|---|
| Ara h 2 | 2S albumin (storage protein) | Primary sensitisation — heat-stable, gut-resistant | High (anaphylaxis risk) |
| Ara h 1, 3, 6 | Storage proteins | Primary sensitisation | High |
| Ara h 8 | PR-10 (Bet v 1 homologue) | Cross-reactivity with birch pollen | Low (oral allergy syndrome only) |
| Ara h 9 | Lipid transfer protein (LTP) | Cross-reactivity with LTPs in fruit, vegetables | Moderate (variable) |
A patient positive to peanut on conventional testing could have any of the above. Ara h 8 positivity alone does not warrant a peanut-free diet or EpiPen prescription. Ara h 2 positivity does. Without molecular testing, you cannot tell them apart from a whole-extract positive.
This is the concept that molecular testing makes actionable. Sensitisation means your immune system has made IgE antibodies to an allergen protein. Allergy means that sensitisation is producing symptoms when you encounter that allergen in real life.
Around 30–50% of people in Europe are sensitised to at least one common environmental allergen. Many of them have no symptoms whatsoever. A positive skin prick test does not automatically mean you have a clinically significant allergy — it means your immune system has encountered and responded to something, which is a normal part of immune function.
Molecular testing identifies the specific proteins driving sensitisation. This allows a clinician to categorise each reaction:
IgE to species-specific proteins that are stable, gut-resistant, and cause genuine systemic reactions. Management: avoidance, emergency medication, consider immunotherapy.
IgE to pan-allergens shared across species. Usually causes only mild, local symptoms (oral allergy syndrome). Often no dietary avoidance needed; treat the primary pollen driver instead.
IgE to CCDs (cross-reactive carbohydrate determinants) or minor components with no documented clinical significance. Positive test but unlikely to cause relevant symptoms.
Pan-allergens are proteins that appear across many different biological species. Because your immune system learns to recognise the protein structure rather than its origin, sensitisation to a pan-allergen in one species often means positive tests across multiple apparently unrelated sources. Understanding pan-allergens explains many puzzling allergy patterns.
| Pan-allergen family | Prototype | Typical cross-reactions | Clinical risk |
|---|---|---|---|
| PR-10 proteins | Bet v 1 (birch pollen) | Apple, pear, cherry, peach, hazelnut, celery, carrot, soy | Low — oral itching only (OAS); cooked versions usually tolerated |
| Profilins | Phl p 12 (timothy grass) | Most fruits, vegetables, latex, pollens | Low — mild OAS; can cause false positives on many foods |
| LTPs (lipid transfer proteins) | Pru p 3 (peach) | Stone fruits, rosaceae, grape, corn, peanut, mustard | Moderate–high — can cause systemic reactions; more clinically significant than PR-10 |
| Tropomyosins | Der p 10 (house dust mite) | Shellfish, cockroach, other crustaceans | High — major food allergy component in shellfish-sensitive patients |
| CCDs | MUXF3 | Wide cross-reactivity across plants and insects | Very low — largely clinically irrelevant despite positive IgE |
The practical value of identifying pan-allergens is significant. A patient who tests positive to apple, pear, peach, cherry, hazelnut, celery, and carrot might fear a long list of dangerous food allergies. If molecular testing shows this is entirely PR-10-driven by birch pollen sensitisation, the picture changes completely: they can eat most of these foods cooked without risk, they don't need to carry an EpiPen for stone fruit, and the primary intervention is treating their birch pollen hay fever — not dietary avoidance.
ALEX3 (Allergy Explorer 3) is a microarray-based molecular testing platform that screens IgE antibodies against more than 300 individual allergen components in a single blood sample. It was developed in Austria and is now used in allergy clinics across Europe.
The test uses a small blood sample (one tube). A microarray chip containing the 300+ individual molecular allergen components is incubated with the patient's serum. IgE antibodies in the serum bind to their target components, and the binding is quantified using fluorescent labelling. The result is a component-level sensitisation profile: not "positive to grass" but specific IgE values against Phl p 1, Phl p 5, Phl p 12 and other individual grass proteins.
The test is most valuable when the conventional result either doesn't explain the patient's symptoms or would lead to disproportionate management if taken at face value. Key scenarios:
Allergen immunotherapy (AIT) only works for genuine primary sensitisation. If hay fever symptoms are driven by grass pollen Phl p 1/5, sublingual immunotherapy targeting grass will work. If they're driven by profilin cross-reactivity, it will not — the patient is sensitised to a pan-allergen across dozens of species, and single-source IT cannot address that. Molecular profiling is essential before starting IT.
Patients told to avoid peanut based on a positive skin prick test may have decades of unnecessary restriction if they're actually Ara h 8 positive (birch cross-reactivity) rather than Ara h 2 positive. Similarly, a positive soy IgE in a birch-sensitive patient is usually Gly m 4 (PR-10 cross-reactivity) rather than primary soy allergy — with entirely different management implications.
After a severe systemic reaction, molecular testing can identify the trigger and risk-stratify precisely. Bee venom allergy driven by Api m 1 (hyaluronidase) has a different prognosis and management pathway than sensitisation to Api m 10 (icarapin). For wasp allergy, distinguishing Ves v 1 from Ves v 5 changes the immunotherapy protocol. This level of detail is not available from whole-extract testing.
Patients with 10+ positive results on standard testing can be difficult to manage clinically. Molecular testing frequently shows that many of those positives are driven by one or two pan-allergens — a birch/LTP combination, for example — reducing apparent complexity to manageable primary sensitisations. This changes avoidance lists, medication choices, and referral decisions significantly.
| Skin prick test | Specific IgE (whole extract) | Molecular (ALEX3) | |
|---|---|---|---|
| What it detects | Wheal response to allergen extract | IgE to whole allergen in serum | IgE to specific individual proteins |
| Number of allergens | Typically 10–20 per session | Individual tests per allergen | 300+ components in one blood draw |
| Cross-reactivity resolution | ❌ Cannot distinguish | ❌ Cannot distinguish | ✅ Yes — identifies pan-allergens |
| Anaphylaxis risk stratification | Limited | Limited | ✅ Yes — storage protein vs PR-10 |
| Guides immunotherapy choice | Partially | Partially | ✅ Definitively |
| Requires skin reaction | Yes — antihistamines must be stopped | No | No |
| Clinical setting | Clinic (immediate result) | Laboratory (48–72hrs) | Laboratory (5–7 days) |
Molecular testing is not a replacement for clinical assessment or skin prick testing. It is most powerful when used as a second-tier investigation: after initial testing has identified broad sensitisation, molecular data resolves the clinical significance and guides management. For patients with straightforward presentations — single clear allergen, predictable symptoms, good response to standard treatment — conventional testing is entirely adequate.
300+ allergen components in a single blood test. Results reviewed by a clinician experienced in molecular allergy data interpretation.
From £295 · Results within 5–7 days · Surbiton, Surrey
300+ molecular allergen components from a single blood sample.
Molecular testing identifies sensitisation patterns — it does not replace clinical assessment. IgE levels do not directly correlate with symptom severity. Results should always be interpreted in the context of your clinical history by an experienced clinician.